Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream

Dermatologic Surgery

Volumn 28, Issue 6, 2002, Pages 518-523

  Weisberg, Noah Kawika ^a   Varghese, Matthew ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; ISOTRETINOIN;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER PREVENTION; CASE REPORT; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CREAM; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; SIBLING; TREATMENT FAILURE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG TOLERANCE; FACIAL NEOPLASMS; FEMALE; HUMANS; MALE; OINTMENTS; SKIN NEOPLASMS; XERODERMA PIGMENTOSUM;

EID: 0036288305     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2002.01196.x     Document Type: Article

References (18)

1. Xeroderma pigmentosum: Cutaneous, ocular, and neurologic abnormalities in 830 published cases
2. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer: The xeroderma pigmentosum paradigm
3. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin
4. Chemoprevention of skin cancer in xeroderma pigmentosum
5. Retinoid chemoprevention in patients at high risk for skin cancer
6. Cytokine induction by the immunomodulators imiquimod and S-27609
7. Imiquimod 5% cream
8. Treatment of genital warts with an immune-response modifier (imiquimod)
9. Self-administered topical 5% imiquimod cream for external anogenital warts
10. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
11. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient
12. Topical imiquimod treatment of a cutaneous melanoma metastasis
13. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1 positive man
14. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac: Potential applications for this combination of immunotherapy
15. Imiquimod 5% cream in the treatment of Bowen's disease
16. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial
17. Editorial commentary to: The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient